Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Everyone at CCTG would like to congratulate Dr Joseph Connors for his recent appointment to the Order of Canada, as one of 114 Canadian appointees “whose service has shaped our society; whose innovations ignite our imaginations; and whose compassion unites our communities.”
As with most events in 2020 the 62nd American Society of Hematology Annual Meeting and Exposition was a virtual meeting held December 5-8. There were four presentations of note for trials that CCTG participated in.
Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low, do not benefit from chemotherapy when it is added to hormone therapy, according to initial results from the MAC15 RxPONDER trial presented at the 2020 San Antonio Breast Cancer Symposium.
MAC21 (NCT02927249), A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial, has closed to accrual after completion of target accrual.
The HDC1 study: A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma has been centrally activated in Canada.
Congratulations from CCTG! The Canadian Cancer Society (CCS) has funded its first research grant focused specifically on rare and aggressive uterine cancers, a critical first step to better outcomes for people with these cancers to Dr Stephanie Lheureux.
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Head and Neck Disease Site Committee (cancer inside the nose, throat or mouth).
The COVID 19 pandemic increased focus on mechanisms to oversee clinical studies remotely in order to limit travel and number of visitors to clinical trial sites. The Canadian Cancer Trials Group (CCTG) created the Remote Auditing and Monitoring Working Group (RAM WG) this past summer to support CCTG member centres navigate new ways of working with respect to remote monitoring and auditing practices.